{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:16:14Z","timestamp":1792016174344,"version":"4.4.0"},"reference-count":92,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, and it leads to end-stage renal disease (ESRD). The clinical manifestations of ADPKD are variable, with extreme differences observable in its progression, even among members of the same family with the same genetic mutation. In an age of new therapeutic options, it is important to identify patients with rapidly progressive evolution and the risk factors involved in the disease\u2019s poor prognosis. As the pathophysiological mechanisms of the formation and growth of renal cysts have been clarified, new treatment options have been proposed to slow the progression to end-stage renal disease. Furthermore, in addition to the conventional factors (PKD1 mutation, hypertension, proteinuria, total kidney volume), increasing numbers of studies have recently identified new serum and urinary biomarkers of the disease\u2019s progression, which are cheaper and more easily to dosing from the early stages of the disease. The present review discusses the utility of new biomarkers in the monitoring of the progress of ADPKD and their roles in new therapeutic approaches.<\/jats:p>","DOI":"10.3390\/medicina59050915","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:29:01Z","timestamp":1683779341000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease\u2014The Promised Land?"],"prefix":"10.3390","volume":"59","author":[{"given":"Camelia","family":"Pana","sequence":"first","affiliation":[{"name":"Nephrology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Mihaela","family":"Stanigut","sequence":"additional","affiliation":[{"name":"Nephrology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Cimpineanu","sequence":"additional","affiliation":[{"name":"Medical Semiology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Alexandru","sequence":"additional","affiliation":[{"name":"Nephrology Department, Constanta County Emergency Hospital, 900601 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camer","family":"Salim","sequence":"additional","affiliation":[{"name":"Emergency Department, Constanta County Emergency Hospital, 900601 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Doina","family":"Nicoara","sequence":"additional","affiliation":[{"name":"Medical Semiology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periha","family":"Resit","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900601 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Ana","family":"Tuta","sequence":"additional","affiliation":[{"name":"Nephrology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease; Harris PC. Mutations in GANAB, Encoding the Glucosidase II\u03b1 Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1681\/ASN.2016121312","article-title":"Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase","volume":"28","author":"Cabezas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","first-page":"477","article-title":"Polycystic kidney disease re-evaluated: A population-based study","volume":"79","author":"Davies","year":"1991","journal-title":"QJM Int. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Solazzo, A., Testa, F., Giovanella, S., Busutti, M., Furci, L., Carrera, P., Ferrari, M., Ligabue, G., Mori, G., and Leonelli, M. (2018). The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190430"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ackd.2010.01.002","article-title":"Molecular advances in autosomal dominant polycystic kidney disease","volume":"17","author":"Gallagher","year":"2010","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Leierer, J., Perco, P., Hofer, B., Eder, S., Dzien, A., Kerschbaum, J., Rudnicki, M., and Mayer, G. (2021). Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136885"},{"key":"ref_9","first-page":"69","article-title":"Polycystic kidney disease: Inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0092-8674(00)81793-6","article-title":"The molecular basis of focal cyst formation in human ADPKD type 1","volume":"87","author":"Qian","year":"1996","journal-title":"Cell"},{"key":"ref_12","unstructured":"Tu\u021b\u0103, L.-A. (2017). Actualit\u0103\u0163i \u00een Boala Polichistic\u0103 Renal\u0103 Autozomal Dominant\u0103, Editura Etna."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2215\/CJN.05651207","article-title":"Strategies to Inhibit Cyst Formation in ADPKD","volume":"3","author":"Calvet","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00109-019-01770-4","article-title":"Plasma membrane localized TMEM16 proteins are Indispensable for expression of CFTR","volume":"97","author":"Benedetto","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-10-2041-4_2","article-title":"Genetic mechanisms of ADPKD","volume":"933","author":"Kim","year":"2016","journal-title":"Cystogenesis Adv. Exp. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.kint.2020.02.008","article-title":"Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease","volume":"98","author":"Song","year":"2020","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102501","DOI":"10.1016\/j.ceca.2021.102501","article-title":"The Mitochondrial Ca2+ import complex is altered in ADPKD","volume":"101","author":"Yanda","year":"2022","journal-title":"Cell Calcium"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00337-17","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.mcb.2019.05.008","article-title":"In vitro cyst formation of ADPKD cells","volume":"153","author":"Sharma","year":"2019","journal-title":"Methods Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Petzold, K., Poster, D., Krauer, F., Spanaus, K., Andreisek, G., Nguyen-Kim, T.D.L., Pavik, I., Ho, T.A., Serra, A.L., and Rotar, L. (2015). Urinary biomarkers at early ADPKD disease stage. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123555"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis","volume":"56","author":"Meijer","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000502999","article-title":"Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors","volume":"50","author":"Messchendorp","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2021.03.893","article-title":"Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease","volume":"6","author":"Janssens","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1681\/ASN.2018080810","article-title":"Tissue-resident macrophages promote renal cystic disease","volume":"30","author":"Zimmerman","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109648","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00109-020-01964-1","article-title":"Macrophage migration inhibitory factor is regulated by HIF-1\u03b1 and cAMP and promotes renal cyst cell proliferation in a macrophage-independent manner","volume":"98","author":"Safi","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1172\/JCI80467","article-title":"Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term Effects of Tolvaptan in Individuals with Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ekir.2019.08.010","article-title":"Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients","volume":"4","author":"Hanudel","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ekir.2021.01.012","article-title":"Evaluation of Urinary Biomarkers of Proximal Tubular Injury, Inflammation, and Fibrosis in Patients with Albuminuric and Nonalbuminuric Diabetic Kidney Disease","volume":"6","author":"Phanish","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","article-title":"Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients with a High Likelihood of Disease Progression","volume":"3","author":"Messchendorp","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2215\/CJN.09941014","article-title":"Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan","volume":"10","author":"Harskamp","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000524586","article-title":"Urinary Epidermal Growth Factor: A Promising \u201cNext Generation\u201d Biomarker in Kidney Disease","volume":"53","author":"Cortvrindt","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ckj\/sfz105","article-title":"Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease","volume":"13","author":"Martin","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1159\/000495389","article-title":"Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease","volume":"43","author":"Watanabe","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.23876\/j.krcp.21.303","article-title":"Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression","volume":"41","author":"Kim","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000448296","article-title":"Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression","volume":"134","author":"Hian","year":"2016","journal-title":"Nephron"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/ki.2013.515","article-title":"Urinary Angiotensinogen Can Be Useful for Screening Patients with Polycystic Kidney Disease","volume":"85","author":"Kocyigit","year":"2014","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Park, H.C., Kang, A.Y., Jang, J.Y., Kim, H., Han, M., Oh, K.-H., Kim, S.H., Noh, J.W., Cheong, H.I., and Hwang, Y.-H. (2015). Increased Urinary Angiotensinogen\/Creatinine (AGT\/Cr) Ratio May Be Associated with Reduced Renal Function in Autosomal Dominant Polycystic Kidney Disease Patients. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0075-8"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 Promotes Cyst Progression in a Mouse Model of Autosomal Dominant Polycystic Kidney Disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s42003-018-0200-x","article-title":"Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways","volume":"1","author":"Podrini","year":"2018","journal-title":"Commun. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"740087","DOI":"10.3389\/fmed.2021.740087","article-title":"Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD","volume":"8","author":"Pagliarini","year":"2021","journal-title":"Front. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.34067\/KID.0005962020","article-title":"Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants","volume":"2","author":"Hallows","year":"2021","journal-title":"Kidney360"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ekir.2022.11.019","article-title":"Association of Longitudinal Urinary Metabolic Biomarkers with ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants","volume":"8","author":"Hallows","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100013","DOI":"10.1016\/j.bbadva.2021.100013","article-title":"Urinary exosome proteomic profiling defines stage-specific rapid progression of autosomal dominant polycystic kidney disease and tolvaptan efficacy","volume":"1","author":"Raby","year":"2021","journal-title":"BBA Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-physiol-031620-092817","article-title":"Uromodulin: Roles in Health and Disease","volume":"83","author":"Schaeffer","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fragiadaki, M., Macleod, F.M., and Ong, A.C.M. (2020). The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238936"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000524851","article-title":"Change in Urinary Myoinositol\/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients","volume":"53","author":"Dekker","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1172\/JCI128503","article-title":"Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease","volume":"129","author":"Torres","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/ndt\/gfy020","article-title":"Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate","volume":"33","author":"Gil","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Dekker, S.E.I., Verhoeven, A., Soonawala, D., Peters, D.J.M., de Fijter, J.W., and Mayboroda, O.A. (2020). Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233213"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1152\/ajprenal.00262.2021","article-title":"Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease","volume":"322","author":"Hopp","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/nep.13957","article-title":"Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease","volume":"26","author":"Saravanabavan","year":"2021","journal-title":"Nephrology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wei, Z., Kwan, B.C., Chow, K.M., Cheng, P.M.-S., Luk, C.C.-W., Lai, K.-B., Li, P.K.-T., and Szeto, C.C. (2018). Urinary mitochondrial DNA level as a biomarker of tissue injury in non-diabetic chronic kidney diseases. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1178-9"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1006427","DOI":"10.3389\/fphys.2022.1006427","article-title":"Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1002\/jcp.26473","article-title":"MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR\/MDM2 pathway in ADPKD cells","volume":"233","author":"Mangolini","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_61","unstructured":"Saravanabavan, S., Munt, A., Wong, A., and Rangan, G. (September, January 28). Mitochondrial Dna Copy Number Variation as a Predictor of Disease Severity in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Proceedings of the 56th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Online."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ben-Dov, I.Z., Tan, Y.-C., Morozov, P., Wilson, P.D., Rennert, H., Blumenfeld, J.D., and Tuschl, T. (2014). Urine MicroRNA as Potential Biomarkers of Autosomal Dominant Polycystic Kidney Disease Progression: Description of miRNA Profiles at Baseline. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086856"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1523-1755.2001.00065.x","article-title":"Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats","volume":"60","author":"Cowley","year":"2001","journal-title":"Kidney Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary Excretion of Monocyte Chemoattractant Protein-1 in Autosomal Dominant Polycystic Kidney Disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A Tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Xiaogang","year":"2008","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ki.1991.87","article-title":"Cytokines in fluids from polycystic kidneys","volume":"39","author":"Gardner","year":"1991","journal-title":"Kidney Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12967-015-0463-7","article-title":"Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression","volume":"30","author":"Piazzon","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_68","first-page":"59","article-title":"Glomerular hyperfiltration and serum beta 2-microglobulin used as early markers in diagnosis of autosomal dominant polycystic kidney disease","volume":"35","author":"Dimitrakov","year":"1993","journal-title":"Folia Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","article-title":"Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury","volume":"62","author":"Han","year":"2002","journal-title":"Kidney Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000103912","article-title":"Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease","volume":"27","author":"Bolignano","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00000441-200510000-00002","article-title":"Candesartan Reduces Urinary Fatty Acid-Binding Protein Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"330","author":"Nakamura","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"F775","DOI":"10.1152\/ajprenal.00370.2003","article-title":"The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease","volume":"287","author":"Soto","year":"2004","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Holubec","year":"2001","journal-title":"Kidney Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.08.007","article-title":"Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease","volume":"49","author":"Lacquaniti","year":"2013","journal-title":"Peptides"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000500478","article-title":"Systemic Succinate, Hypoxia-Inducible Factor-1 Alpha, and IL-1\u03b2 Gene Expression in Autosomal Dominant Polycystic Kidney Disease with and without hypertension","volume":"9","author":"Kocyigit","year":"2019","journal-title":"Cardiorenal Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1073\/pnas.1301693110","article-title":"miR-17\u223c92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease","volume":"110","author":"Patel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109548","DOI":"10.1016\/j.cellsig.2020.109548","article-title":"Modulation of polycystic kidney disease by non-coding RNAs","volume":"71","author":"Ramalingam","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/iub.2255","article-title":"MiR-182 inhibits kidney fibrosis by regulating transforming growth factor \u03b21\/Smad3 pathway in autosomal dominant polycystic kidney disease","volume":"72","author":"Sun","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ruiz-Manriquez, L.M., Ledesma Pacheco, S.J., Medina-Gomez, D., Uriostegui-Pena, A.G., Estrada-Meza, C., Bandyopadhyay, A., Pathak, S., Banerjee, A., Chakraborty, S., and Srivastava, A. (2022). A Brief Review on the Regulatory Roles of MicroRNAs in Cystic Diseases and Their Use as Potential Biomarkers. Genes, 13.","DOI":"10.3390\/genes13020191"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.xkme.2020.06.013","article-title":"MicroRNAs and Polycystic Kidney Disease","volume":"2","author":"Li","year":"2020","journal-title":"Kidney Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gomotirceanu, A.M., Sab\u0103u, A., Gomot\u00eerceanu, F., Gomot\u00eerceanu, B., Ioni\u021b\u0103, C., and Gliga, M.L. (2023). CEUS utility in the diagnosis of a stage I renal cancer developed on polycystic kidney. A case report. Med. Ultrason.","DOI":"10.11152\/mu-3889"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.34067\/KID.0003902020","article-title":"Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD","volume":"2","author":"Rosenberg","year":"2021","journal-title":"Kidney360"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ki.2009.93","article-title":"Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease","volume":"76","author":"Kistler","year":"2009","journal-title":"Kidney Int."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Houske, E.A., Glimm, M.G., Bergstrom, A.R., Slipher, S.K., Welhaven, H.D., Greenwood, M.C., Linse, G.M., June, R.K., Yu, A.S.L., and Wallace, D.P. (2022). Metabolomic Profiling to Identify Early Urinary Biomarkers and Metabolic Pathway Alterations in Autosomal Dominant Polycystic Kidney Disease. bioRxiv.","DOI":"10.1101\/2022.12.08.519365"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"753418","DOI":"10.3389\/fmed.2022.753418","article-title":"AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target","volume":"9","author":"Caplan","year":"2022","journal-title":"Front. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"109704","DOI":"10.1016\/j.cellsig.2020.109704","article-title":"Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease","volume":"73","author":"Song","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/ars.2021.0194","article-title":"Urinary Thioredoxin as a Biomarker of Renal Redox Dysregulation and a Companion Diagnostic to Identify Responders to Redox-Modulating Therapeutics","volume":"36","author":"Kasuno","year":"2022","journal-title":"Antioxid. Redox Signal."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12882-019-1290-5","article-title":"Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: An exploratory analysis using the ADPKD outcomes model","volume":"20","author":"Bennett","year":"2019","journal-title":"BMC Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kistler, A.D., Serra, A.L., Siwy, J., Poster, D., Krauer, F., Torres, V.E., Mrug, M., Grantham, J.J., Bae, K.T., and Bost, J.E. (2013). Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. PLoS ONE, 8.","DOI":"10.1371\/annotation\/9281c713-d253-4a1a-8255-92e691e77a24"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1681\/ASN.2015090994","article-title":"Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease","volume":"27","author":"Salih","year":"2016","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:18Z","timestamp":1760124738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["medicina59050915"],"URL":"https:\/\/doi.org\/10.3390\/medicina59050915","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}